These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 36413739)

  • 1. A Pilot Mixed-Methods Study of Malignant Pleural Mesothelioma Symptoms.
    Walker SL; Vaughan Dickson V; Cacchione PZ
    Oncol Nurs Forum; 2022 Oct; 49(6):615-623. PubMed ID: 36413739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Content validity and electronic PRO (ePRO) usability of the Lung Cancer Symptom Scale-Mesothelioma (LCSS-Meso) in mesothelioma patients.
    Gelhorn HL; Skalicky AM; Balantac Z; Eremenco S; Cimms T; Halling K; Hollen PJ; Gralla RJ; Mahoney MC; Sexton C
    Support Care Cancer; 2018 Jul; 26(7):2229-2238. PubMed ID: 29392480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced Symptom Management System for Patients with Malignant Pleural Mesothelioma (ASyMSmeso): Mixed Methods Study.
    Maguire R; Connaghan J; Arber A; Klepacz N; Blyth KG; McPhelim J; Murray P; Rupani H; Chauhan A; Williams P; McNaughton L; Woods K; Moylan A
    J Med Internet Res; 2020 Nov; 22(11):e19180. PubMed ID: 33180025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Malignant pleural mesothelioma: treatment patterns and humanistic burden of disease in Europe.
    Moore A; Bennett B; Taylor-Stokes G; McDonald L; Daumont MJ
    BMC Cancer; 2022 Jun; 22(1):693. PubMed ID: 35739480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adapting the Lung Cancer Symptom Scale (LCSS) to mesothelioma: using the LCSS-Meso conceptual model for validation.
    Hollen PJ; Gralla RJ; Liepa AM; Symanowski JT; Rusthoven JJ
    Cancer; 2004 Aug; 101(3):587-95. PubMed ID: 15274072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modification of existing patient-reported outcome measures: qualitative development of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM).
    Williams LA; Whisenant MS; Mendoza TR; Haq S; Keating KN; Cuffel B; Cleeland CS
    Qual Life Res; 2018 Dec; 27(12):3229-3241. PubMed ID: 30187393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Malignant pleural mesothelioma: diagnostic value of medical thoracoscopy and long-term prognostic analysis.
    Xu LL; Yang Y; Wang Z; Wang XJ; Tong ZH; Shi HZ
    BMC Pulm Med; 2018 Apr; 18(1):56. PubMed ID: 29615010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing malignant pleural mesothelioma: experience and perceptions of health care professionals caring for people with mesothelioma.
    Warby A; Dhillon HM; Kao S; Vardy JL
    Support Care Cancer; 2019 Sep; 27(9):3509-3519. PubMed ID: 30684047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multidetector CT Findings and Differential Diagnoses of Malignant Pleural Mesothelioma and Metastatic Pleural Diseases in Korea.
    Kim YK; Kim JS; Lee KW; Yi CA; Goo JM; Jung SH
    Korean J Radiol; 2016; 17(4):545-53. PubMed ID: 27390546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
    Guarrera S; Viberti C; Cugliari G; Allione A; Casalone E; Betti M; Ferrante D; Aspesi A; Casadio C; Grosso F; Libener R; Piccolini E; Mirabelli D; Dianzani I; Magnani C; Matullo G
    J Thorac Oncol; 2019 Mar; 14(3):527-539. PubMed ID: 30408567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743.
    Scherpereel A; Antonia S; Bautista Y; Grossi F; Kowalski D; Zalcman G; Nowak AK; Fujimoto N; Peters S; Tsao AS; Mansfield AS; Popat S; Sun X; Lawrance R; Zhang X; Daumont MJ; Bennett B; McKenna M; Baas P
    Lung Cancer; 2022 May; 167():8-16. PubMed ID: 35367910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing a fit-for-purpose composite symptom score as a symptom burden endpoint for clinical trials in patients with malignant pleural mesothelioma.
    Cleeland CS; Keating KN; Cuffel B; Elbi C; Siegel JM; Gerlinger C; Symonds T; Sloan JA; Dueck AC; Bottomley A; Wang XS; Williams LA; Mendoza TR
    Sci Rep; 2024 Jun; 14(1):14839. PubMed ID: 38937473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial.
    Banna GL; Addeo A; Zygoura P; Tsourti Z; Popat S; Curioni-Fontecedro A; Nadal E; Shah R; Pope A; Fisher P; Spicer J; Roy A; Gilligan D; Gautschi O; Janthur WD; López-Castro R; Roschitzki-Voser H; Dafni U; Peters S; Stahel RA
    Lung Cancer; 2022 Jul; 169():77-83. PubMed ID: 35660972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Communication of a mesothelioma diagnosis: developing recommendations to improve the patient experience.
    Taylor BH; Warnock C; Tod A
    BMJ Open Respir Res; 2019; 6(1):e000413. PubMed ID: 31179006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: A retrospective study in a single center.
    Otoshi T; Kataoka Y; Ikegaki S; Saito E; Matsumoto H; Kaku S; Shimada M; Hirabayashi M
    PLoS One; 2017; 12(10):e0185850. PubMed ID: 28968445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome.
    Ortolan E; Giacomino A; Martinetto F; Morone S; Lo Buono N; Ferrero E; Scagliotti G; Novello S; Orecchia S; Ruffini E; Rapa I; Righi L; Volante M; Funaro A
    Oncotarget; 2014 Aug; 5(15):6191-205. PubMed ID: 25026285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The degree of microRNA-34b/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma.
    Muraoka T; Soh J; Toyooka S; Aoe K; Fujimoto N; Hashida S; Maki Y; Tanaka N; Shien K; Furukawa M; Yamamoto H; Asano H; Tsukuda K; Kishimoto T; Otsuki T; Miyoshi S
    Lung Cancer; 2013 Dec; 82(3):485-90. PubMed ID: 24168922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expression and clinical significance of COL1A1 and COL1A2 genes in malignant pleural mesothelioma tissues].
    Li B; Pu YQ; Li ZL; Zhao Y; Zi JJ; Xiong W
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2022 Jul; 40(7):487-494. PubMed ID: 35915937
    [No Abstract]   [Full Text] [Related]  

  • 19. On the diagnosis of malignant pleural mesothelioma: A necropsy-based study of 171 cases (1997-2016).
    Barbieri PG; Mirabelli D; Magnani C; Brollo A
    Tumori; 2019 Aug; 105(4):304-311. PubMed ID: 29714657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma.
    Yamada S; Tabata C; Tabata R; Fukuoka K; Nakano T
    Clin Chem Lab Med; 2011 Oct; 49(10):1721-6. PubMed ID: 21692685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.